Funding for this research was provided by:
National Institute of Dental and Craniofacial Research (R01DE027346, U24DE029463)
Received: 20 April 2022
Accepted: 11 June 2022
First Online: 17 June 2022
: All animal experiments were conducted in accordance with the animal welfare guidelines and approval of the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University.
: Not applicable.
: MTL and GCG own equity in TauTona group which supplied the DFO patches. GCG owns a patent for transdermal delivery of HIF1α modulators. GCG, MTL and DCW hold a patent for the application of DFO for the treatment of irradiated tissue. All other authors have no conflict of interest.